

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT  
TO RULE 13a-16 or 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of May, 2019**

Commission File Number: 001-38452

**MEREO BIOPHARMA GROUP PLC**

(Translation of registrant's name into English)

**4<sup>th</sup> Floor, One Cavendish Place,  
London, W1G 0QF, United Kingdom**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

## Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

### Notice of AGM

**London, May 20, 2019** - Merco BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today announces that its Annual General Meeting is to be held on June 19, 2019 at 3:00 p.m. (London time) at the Marlborough Theatre, The King's Fund, 11-13 Cavendish Square, London W1G 0AN, United Kingdom.

A copy of the Notice of Annual General Meeting is available on the Company's website: [www.mereobiopharma.com](http://www.mereobiopharma.com).

### About Merco

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Merco's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Merco's four product candidates have previously generated positive clinical data for Merco's target indications or in related indications. Merco has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Merco added two candidates to its pipeline, Navicixizumab and Etigilimab.

- BPS-804 for osteogenesis imperfecta (OI). In October 2018, the Company announced completion of enrollment of 112 adult patients in a Phase 2b dose ranging study with initial data expected in Q2 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved by the EMA. BPS-804 has orphan designation in the U.S. and the EU and has been accepted into the PRIME and Adaptive Pathways in EU;
- MPH-966 for alpha-1 antitrypsin deficiency (AATD). The Company recently announced dosing of the first patient in a Phase 2 dose ranging study in the U.S. with data expected around the end of 2019;
- BCT-197 for severe exacerbations of COPD. The Company announced positive Phase 2 data in May 2018 and recently announced the outline of the pivotal Phase 3 study including the primary and key secondary endpoints following the successful end of Phase 2 Type B meeting with the FDA;
- BGS-649 for hypogonadotropic hypogonadism (HH). The Company announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension study in December 2018;
- Navicixizumab has completed a Phase 1a single-agent clinical trial in patients with advanced solid tumors and is currently in a Phase 1b trial in combination with a standard paclitaxel regimen in patients with platinum-resistant ovarian cancer. This study recently completed enrolment; and
- Etigilimab has completed a single-agent Phase 1a trial in patients with advanced or metastatic solid tumors and is currently in a Phase 1b combination study with nivolumab. Etigilimab is part of OncoMed's prior collaboration with Celgene. Celgene has the option to obtain an exclusive licence to develop and commercialize the product. If Celgene exercises such option, OncoMed (now a wholly-owned indirect subsidiary of Merco) will be eligible to receive a \$35 million opt in payment.

### Further Enquiries

#### Mereo

Denise Scots-Knight, Chief Executive Officer  
Richard Jones, Chief Financial Officer

**+44 (0)333 023 7300**

#### Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Merco)

Phil Davies  
Will Goode

**+44 (0)20 7894 7000**

#### RBC Capital Markets (Joint Broker to Merco)

Rupert Walford  
Jamil Miah

**+44 (0)20 7653 4000**

#### FTI Consulting (Public Relations Adviser to Merco)

Simon Conway  
Brett Pollard

**+44 (0)20 3727 1000**

#### Burns McClellan (US Public Relations Adviser to Merco)

Lisa Burns  
Jill Steier

**+01 (0) 212 213 0006**

---



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 21, 2019

**MEREO BIOPHARMA GROUP PLC**

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel

---